Search

• A facile methodology for novel cyclopeptide p53-MDM2 inhibitors with isoindo-linone synthesis has been developed based on photo-induced single electron transfer reaction (SET). • The effect of compound 1 on mitochondrial membrane potential and intracellular Ca2+ concentration have been studied extensively to evaluate the antitumor potential. • The molecular docking suggested that compound 1 presented stronger binding with MDM2 oncoprotein of liver cancer cells, and indicating that compound 1 is a potential inhibitor of MDM2 interactions. In this paper, two kinds of novel p53 cyclopeptides containing 1-Phe, 2-Trp, 3-Leu, 4-Leu/Pro residues and isoindolinone were synthesized by intramolecular photoinduced single electron transfer cyclization reactions, and their structures were confirmed by 1H NMR, 13C NMR and HR-MS. Comparison of bioactivity of compound 1 and 2 against HeLa, HepG-2, MDA-MB, MCF-7 and 4T1 cell lines by MTT assay, indicated moderate antiproliferative activity of compound 2 (4-Pro). Moreover, compound 1 (4-Leu) with isoindolinone fragments exhibited the strongest antiproliferative activity against HepG-2 cell line with an IC 50 of 9.54 μg/mL. The effect of compound 1 on mitochondrial membrane potential and intracellular Ca2+ concentration have been studied to evaluate the antitumor potential. The decrease of mitochondrial membrane potential and the increase of intracellular Ca2+ concentration indicated compound 1 had the excellent antitumor activity. Especially for compound 1 , the molecular docking suggested that 4-Leu residue and isoindolinone fragments presented stronger binding with MDM2 oncoprotein of liver cancer cells, which plays an important role in the stability of MDM2 ligands. [Display omitted] [ABSTRACT FROM AUTHOR]

Photoinduced single electron transfer (SET) cyclization processes for synthesis of a Sansalvamide A analog containing double pharmacophores (cyclicpeptides and O-phthalimide moiety) is described to develop novel antitumor cyclopeptide drug. The resultant compound is active in drug-sensitive HeLa, HepG-2 and MCF-7 cell lines. Specifically, the title compound was found to inhibit MCF-7 cells with an IC 50 value of 15 μM (13.4 μg/mL), which may serve as a potential candidate for antitumor drug development. [ABSTRACT FROM AUTHOR]